Timothy Scannell Sells 2,945 Shares of NovoCure (NASDAQ:NVCR) Stock

Posted by Brian Himes on Jun 5th, 2026

NovoCure Limited (NASDAQ:NVCR – Get Free Report) Director Timothy Scannell sold 2,945 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $15.77, for a total value of $46,442.65. Following the completion of the sale, the director directly owned 14,288 shares of the company’s stock, valued at $225,321.76. This represents a 17.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

NovoCure Stock Up 11.4%

NVCR opened at $17.99 on Friday. NovoCure Limited has a 1-year low of $9.82 and a 1-year high of $19.25. The company has a current ratio of 2.90, a quick ratio of 2.70 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $2.08 billion, a price-to-earnings ratio of -11.76 and a beta of 0.93. The business has a 50 day moving average of $14.29 and a 200-day moving average of $13.19.

NovoCure (NASDAQ:NVCR – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). NovoCure had a negative net margin of 25.66% and a negative return on equity of 50.82%. The business had revenue of $174.06 million during the quarter, compared to the consensus estimate of $167.77 million. During the same period in the prior year, the company posted ($0.31) earnings per share. The firm’s revenue was up 12.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that NovoCure Limited will post -1.55 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on NVCR. Wells Fargo & Company increased their price objective on NovoCure from $13.50 to $17.00 and gave the company an “equal weight” rating in a research report on Monday, May 4th. HC Wainwright raised their target price on NovoCure from $47.00 to $49.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Evercore reaffirmed an “outperform” rating on shares of NovoCure in a research report on Friday, May 1st. Weiss Ratings raised NovoCure from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. Finally, Wedbush reaffirmed a “neutral” rating and issued a $18.00 target price on shares of NovoCure in a research report on Thursday, April 16th. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $27.29.

Get Our Latest Research Report on NovoCure

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of NVCR. Empowered Funds LLC bought a new position in NovoCure in the fourth quarter worth $33,000. Kestra Advisory Services LLC bought a new position in NovoCure in the fourth quarter worth $49,000. Larson Financial Group LLC lifted its position in NovoCure by 662.1% in the third quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock worth $53,000 after purchasing an additional 3,562 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of NovoCure by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,442 shares of the medical equipment provider’s stock valued at $70,000 after acquiring an additional 1,120 shares during the period. Finally, Acadian Asset Management LLC bought a new position in shares of NovoCure during the first quarter valued at $87,000. 84.61% of the stock is owned by institutional investors.

NovoCure Company Profile

(Get Free Report)

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.